Unified Platform Focus
The ImmunoSync Platform is a single, integrated decision-support system that delivers immune-timing intelligence to both clinical care teams and research organisations. It provides real-time, personalised recommendations that optimise the delivery of chemotherapy, radiotherapy, immunotherapy, and investigational agents without requiring any change to standard treatment protocols.
The ImmunoSync Platform supports oncology care providers by mapping each patient’s unique immune cycle to identify the optimal windows for administering existing treatments. Through biomarker analysis and predictive algorithms, it delivers clear, actionable timing recommendations directly to clinicians via a secure interface — enhancing treatment efficacy, improving consistency of outcomes, and addressing unmet needs, particularly for late-stage patients who have exhausted all other treatment options.
- Personalised timing based on individual immune readiness
- Potential for improved local control, survival, and immune-mediated effects (supported by peer-reviewed studies)
- Non-interventional decision-support tool with no changes to standard therapies required
The ImmunoSync Platform partners with leading pharma, biopharma, CROs, and research institutions to incorporate immune cycle insights into clinical development programs. By providing timing optimisation data, it helps refine trial designs, dosing strategies, and combination approaches — potentially reducing development timelines and enhancing overall efficiency.
- Adds an immune-timing layer to existing datasets and trial protocols
- Supports optimisation of therapeutic windows in early- and late-phase studies
- Facilitates data-driven decisions to improve pipeline productivity
Precision Immune Mapping
ImmunoSync identifies the individual characteristics of a patient’s immune system to determine the optimal treatment window.
Biomarker Analysis
ImmunoSync’s proprietary algorithm analyses immune markers to map each patient’s immune system and determine key indicators of immune readiness, supporting both clinical treatment decisions and research protocol optimisation.
Tailored Insights
ImmunoSync adapts its recommendations to the specific therapy modality — whether chemotherapy, radiotherapy, immunotherapy, or investigational agents — ensuring relevance for individual patient care and for industry development programs.
Advanced Analytics
ImmunoSync analyses each patient’s unique immune characteristics to determine the optimal treatment timing window, enabling clinicians to maximise therapeutic impact and assisting industry partners in refining trial designs and combination strategies.
Seamless Integration
ImmunoSync delivers precise, actionable timing recommendations directly to oncology care providers and industry partners, integrating effortlessly into clinical workflows and research/development processes based on the patient’s individual immune profile.
Transforming Oncology Care
Precision Oncology
Treatment synchronised with each patient’s individual immune status, enabling clinicians to deliver therapies at peak readiness and supporting industry partners in optimising protocol timing.
Personalised Care
Tailored to each person’s unique immune profile and treatment plan — whether standard chemotherapy, radiotherapy, immunotherapy, or investigational agents — for enhanced relevance in both clinical practice and research settings.
Enhanced Outcomes
Delivering measurably superior clinical results, including improved local control, survival, and immune-mediated effects, as demonstrated in peer-reviewed studies; extends value to accelerated development and refined trial strategies.
Restored Hope
New treatment options and improved quality of life for late-stage patients with limited alternatives, while providing pharmaceutical and biotechnology partners with tools to advance more effective oncology pipelines.
Clinical Evidence
Key Clinical Evidence
Our research on precision immune mapping has been featured in top-tier medical journals, validating our technology’s effectiveness in revolutionising cancer care approaches.
Novel time-synchronized immune-guided partial tumor irradiation: Proof of principle trial.
Radiotherapy and Oncology — Proof-of-principle trial demonstrating that synchronising radiotherapy delivery with individual immune status significantly improves local control and abscopal effect rates in advanced cancer patients.
▸ View PublicationFaster, Less Toxic, and More Effective: A Holy Trinity in Palliative Radiotherapy — Time-Synchronized Immune-Guided Partial Tumor Irradiation: Proof-of-Principle Trial (NCT04168320).
International Journal of Radiation Oncology, Biology, Physics — Comprehensive analysis showing immune-synchronised partial tumour irradiation achieves faster response, reduced toxicity, and superior outcomes in palliative settings.
▸ View PublicationTime-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment.
Original protocol paper outlining the novel approach of targeting hypoxic tumour segments while preserving the peritumoral immune microenvironment through precision-timed stereotactic body radiotherapy.
▸ View PublicationOur Leadership Team
Get In Touch
Headquarters
Level 3, 179 Queen Street
Melbourne, Victoria 3000
Partnerships
Connect with our team for collaboration in precision oncology.